RxDoctor Payments Data

Robert Drouin

Physician Assistant · Torrington, CTNPI 1629168943

Payments from drug & device makers

$2,062in general payments, 2019–2025

Across 74 payments — averaging $27.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$539
  • Novartis$257
  • E.r. Squibb & Sons, L.L.C.$164
  • Johnson & Johnson$135
  • Silk Road Medical, Inc.$125
  • Lantheus Medical Imaging, Inc.$113
  • plus $729 from 13 others

What the payments were for

  • Food & beverage$2,062100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,062 in reported general payments places this provider in the 85th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$5,362
Medicare patients
60
Services billed
103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban525$550,256
XareltoRivaroxaban107$103,691
EntrestoSacubitril/Valsartan72$97,312
Repatha SureclickEvolocumab78$71,011
JardianceEmpagliflozin32$43,152
Repatha PushtronexEvolocumab22$16,687
Praluent PenAlirocumab11$13,740
VascepaIcosapent Ethyl19$9,531
BrilintaTicagrelor11$8,765
Metoprolol Succinate539$7,504
Rosuvastatin Calcium310$4,010
Atorvastatin Calcium375$3,953
Diltiazem 24hr Er (Cd)Diltiazem Hcl147$3,886
Ezetimibe175$3,303
Dabigatran EtexilateDabigatran Etexilate Mesylate14$3,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$97$550,256525 claims
Johnson & JohnsonXarelto$135$103,691107 claims
NovartisEntresto$257$97,31272 claims
Boehringer IngelheimJardiance$107$43,15232 claims
AstraZenecaBrilinta$86$8,76511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in Torrington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →